Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
2039 studies found for:    "Multiple myeloma"
Show Display Options
Rank Status Study
1 Completed
Has Results
Efficacy of Panobinostat in Patients With Relapsed and Bortezomib-refractory Multiple Myeloma
Conditions: Relapsed and Bortezomib Refractory Multiple Myeloma;   Refractory Multiple Myeloma;   Multiple Myeloma in Relapse
Interventions: Drug: panobinostat;   Drug: bortezomib;   Drug: dexamethasone
2 Active, not recruiting Combination Study of Pomalidomide, Marizomib, and Low-Dose Dexamethasone in Relapsed and Refractory Multiple Myeloma
Conditions: Multiple Myeloma in Relapse;   Refractory Multiple Myeloma;   Multiple Myeloma
Interventions: Drug: pomalidomide;   Drug: marizomib;   Drug: low-dose dexamethasone
3 Completed Vaccine Therapy in Treating Patients With Multiple Myeloma
Conditions: Stage II Multiple Myeloma;   Stage III Multiple Myeloma;   Refractory Plasma Cell Neoplasm
Interventions: Drug: autologous tumor cell vaccine;   Drug: keyhole limpet hemocyanin;   Drug: melphalan;   Drug: sargramostim
4 Completed Bortezomib in Combination With CC-5013 in Patients With Relapsed/Refractory Multiple Myeloma
Conditions: Refractory Multiple Myeloma;   Relapsed Multiple Myeloma;   Multiple Myeloma
Interventions: Drug: Bortezomib;   Drug: CC-5013
5 Terminated
Has Results
A Phase II Trial of Anti-KIR in Smoldering Multiple Myeloma
Conditions: Multiple Myeloma;   Myeloma;   Smoldering Multiple Myeloma
Intervention: Drug: (Anti-KIR)
6 Available Early Patient Access Single Named Patient Program for the Use of Ulocuplumab for the Treatment of Multiple Myeloma
Conditions: Multiple Myeloma in Relapse;   Multiple Myeloma
Interventions: Drug: Ulocuplumab;   Drug: Lenalidomide;   Drug: Bortezomib;   Drug: Dexamethasone
7 Withdrawn Bortezomib Before Donor Stem Cell Transplant in Treating Patients With Multiple Myeloma
Conditions: Multiple Myeloma;   Refractory Multiple Myeloma
Interventions: Procedure: nonmyeloablative allogeneic hematopoietic stem cell transplantation;   Procedure: allogeneic bone marrow transplantation;   Drug: bortezomib;   Drug: melphalan;   Drug: anti-thymocyte globulin;   Drug: sirolimus;   Drug: tacrolimus;   Radiation: total-body irradiation
8 Active, not recruiting Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma
Conditions: Cancer;   Hematologic Malignancies;   Multiple Myeloma;   Oncology;   Bone Metastases;   Multiple Myeloma Bone Lesions
Interventions: Drug: Denosumab;   Drug: Zoledronic acid
9 Completed Study of High Dose Carfilzomib in Multiple Myeloma Patients Who Have Progressed On Standard Dose Carfilzomib
Conditions: Relapse Multiple Myeloma;   Refractory Multiple Myeloma
Intervention: Drug: Carfilzomib
10 Completed Peripheral Stem Cell Transplant in Treating Patients With Multiple Myeloma
Conditions: Multiple Myeloma;   Plasma Cell Neoplasm
Interventions: Biological: filgrastim;   Biological: CD34+ cells;   Drug: cyclophosphamide;   Drug: fludarabine phosphate;   Drug: melphalan;   Drug: methotrexate;   Drug: tacrolimus
11 Completed
Has Results
Plerixafor in Treating Patients With Multiple Myeloma Previously Treated With Lenalidomide and Planning to Undergo Autologous Stem Cell Transplant
Conditions: Multiple Myeloma;   Refractory Multiple Myeloma;   Stage I Multiple Myeloma;   Stage II Multiple Myeloma;   Stage III Multiple Myeloma
Interventions: Drug: plerixafor;   Drug: filgrastim
12 Withdrawn Imaging Studies and the Development of Multiple Myeloma
Conditions: Multiple Myeloma;   Smoldering Multiple Myeloma;   Monoclonal Gammopathy of Undetermined Significance
Intervention: Drug: Fluciclatide
13 Active, not recruiting Vorinostat and Lenalidomide After Autologous Stem Cell Transplant in Treating Patients With Multiple Myeloma
Conditions: Multiple Myeloma;   Plasma Cell Neoplasm
Interventions: Drug: lenalidomide;   Drug: vorinostat
14 Active, not recruiting Lenalidomide and Low-Dose Dexamethasone in Patients With Previously Treated Multiple Myeloma and Kidney Dysfunction
Conditions: Multiple Myeloma;   Plasma Cell Neoplasm
Interventions: Drug: Group A=30-60 CrCl (mL/min);   Drug: Group B=CrCL<30 mL/min not on dialysis;   Drug: Group C=CrCL<30 mL/min and on dialysis
15 Active, not recruiting Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma
Conditions: Multiple Myeloma;   Plasma Cell Neoplasm
Interventions: Drug: etoposide phosphate;   Drug: melphalan;   Drug: topotecan;   Procedure: Autologous Stem Cell Rescue
16 Recruiting Study of Pomalidomide, Cyclophosphamide, Dexamethasone in Relapsed/Refractory Multiple Myeloma
Conditions: Multiple Myeloma in Relapse;   Multiple Myeloma, Refractory
Interventions: Drug: Pomalidomide;   Drug: Cyclophosphamide;   Drug: Dexamethasone
17 Completed
Has Results
Sunitinib in Treating Patients With Relapsed Multiple Myeloma
Conditions: Refractory Multiple Myeloma;   Stage I Multiple Myeloma;   Stage II Multiple Myeloma;   Stage III Multiple Myeloma
Intervention: Drug: sunitinib malate
18 Active, not recruiting
Has Results
Cyclophosphamide, Carfilzomib, Thalidomide, and Dexamethasone in Treating Patients With Newly Diagnosed Active Multiple Myeloma
Conditions: Multiple Myeloma;   Stage I Multiple Myeloma;   Stage II Multiple Myeloma;   Stage III Multiple Myeloma
Interventions: Drug: carfilzomib;   Drug: cyclophosphamide;   Drug: thalidomide;   Drug: dexamethasone
19 Completed
Has Results
S0232 Dexamethasone With or Without Lenalidomide in Treating Patients With Previously Untreated Stage I, Stage II, or Stage III Multiple Myeloma
Conditions: Multiple Myeloma;   Plasma Cell Neoplasm
Interventions: Drug: dexamethasone;   Drug: lenalidomide;   Other: placebo
20 Completed Safety & Efficacy Study of Perifosine + Bortezomib +/- Dexamethasone for Multiple Myeloma Patients
Conditions: Multiple Myeloma;   Multiple Myeloma in Relapse
Interventions: Drug: Perifosine;   Drug: Bortezomib;   Drug: Dexamethasone

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years